177 related articles for article (PubMed ID: 30093631)
1. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
[TBL] [Abstract][Full Text] [Related]
2. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
3. Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.
Gopalswamy M; Kroeger T; Bickel D; Frieg B; Akter S; Schott-Verdugo S; Viegas A; Pauly T; Mayer M; Przibilla J; Reiners J; Nagel-Steger L; Smits SHJ; Groth G; Etzkorn M; Gohlke H
Sci Rep; 2022 Aug; 12(1):14158. PubMed ID: 35986043
[TBL] [Abstract][Full Text] [Related]
4. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
5. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
6. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
7. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
Wichmann C; Becker Y; Chen-Wichmann L; Vogel V; Vojtkova A; Herglotz J; Moore S; Koch J; Lausen J; Mäntele W; Gohlke H; Grez M
Blood; 2010 Jul; 116(4):603-13. PubMed ID: 20430957
[TBL] [Abstract][Full Text] [Related]
8. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the nuclear distribution of the translocation t(8;21)-derived fusion protein AML1/ETO by confocal laser scanning microscopy.
Nagel S; Hambach L; Krauter J; Venturini L; Heidenreich O; Ganser A; Heil G
J Hematother Stem Cell Res; 2002 Apr; 11(2):401-8. PubMed ID: 11983111
[TBL] [Abstract][Full Text] [Related]
11. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
12. Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain.
Bartel Y; Grez M; Wichmann C
Biomed Res Int; 2013; 2013():297692. PubMed ID: 23865046
[TBL] [Abstract][Full Text] [Related]
13. Oligomerization of ETO is obligatory for corepressor interaction.
Zhang J; Hug BA; Huang EY; Chen CW; Gelmetti V; Maccarana M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 2001 Jan; 21(1):156-63. PubMed ID: 11113190
[TBL] [Abstract][Full Text] [Related]
14. Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
Di Genua C; Norfo R; Rodriguez-Meira A; Wen WX; Drissen R; Booth CAG; Povinelli B; Repapi E; Gray N; Carrelha J; Kettyle LM; Jamieson L; Neo WH; Thongjuea S; Nerlov C; Mead AJ
Haematologica; 2019 Nov; 104(11):2215-2224. PubMed ID: 30975913
[TBL] [Abstract][Full Text] [Related]
15. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
[TBL] [Abstract][Full Text] [Related]
17. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
[TBL] [Abstract][Full Text] [Related]
18. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
19. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
[TBL] [Abstract][Full Text] [Related]
20. GFI1 is required for
Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
[No Abstract] [Full Text] [Related]
[Next] [New Search]
